InThera Inc. is a bioventure that pursues the noble cause of developing and commercializing safer and more effective virus-like nanoparticle (VLNP) vaccines against emerging and mutant viral infections.

We are committed to developing innovative and powerful vaccines that elicit immune responses in a safe manner by utilizing highly-efficient and rapid VLNP production technology, a core platform technology based on our patent. Additionally, we aim to commercialize the next generation vaccines against viral infectious diseases for which vaccines are currently unavailable. Our VLNP vaccine production platform, in addition to its efficient and rapid production capability, can be readily applied to a wide range of protein antigens derived from various pathogens. We are confident that our vaccine platform will serve as an effective tool to cope with emerging and mutant viral infections, thus helping people lead safer and healthier lives.

Since its incorporation, InThera has successfully developed multiple vaccine candidates. Recently, we have verified the effectiveness and safety of VLP multivalent vaccine candidate against norovirus through non-clinical studies. In the near future, we will proceed with clinical trials upon IND approval. Moreover, we have completed the non-clinical studies of a new rotavirus vaccine candidate based on protein nanoparticles with the support of the RIGHT Foundation, and we are making good progress toward early clinical trial entry. Using the same platform, we are rapidly expanding our pipeline through the development of new vaccines to respond to global concerns about the potentials for pandemics of infectious diseases that are increasing due to climate change, such as mosquito-borne Dengue fever and Zika virus disease.

CEO
Deog-Young Choi, Ph.D.